ReviewAdvances in pharmacological sciences2019
Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.
Review in Advances in pharmacological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects and Mechanisms of Acupuncture on Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review.Frontiers in neuroscience · 2022Pooled it
- Antioxidant and Anti-Inflammatory Effects of InhaledPlants (Basel, Switzerland) · 2026Article
- Diagnosis and etiology of poststroke depression: A review.World journal of psychiatry · 2025Review
- Luteolin reversed anxiety and depressive-like behavior via modulation of the NF-κB/NLRP3 inflammasome axis in the hippocampus of rats subjected to sleep deprivation.Iranian journal of basic medical sciences · 2024Article
- Review
- Microbial Reprogramming in Obsessive-Compulsive Disorders: A Review of Gut-Brain Communication and Emerging Evidence.International journal of molecular sciences · 2023Review
- The advances of post-stroke depression: 2021 update.Journal of neurology · 2022Review
- Associations of neurotransmitters and the gut microbiome with emotional distress in mixed type of irritable bowel syndrome.Scientific reports · 2022Article
- Natural Products for the Treatment of Post-stroke Depression.Frontiers in pharmacology · 2022Review
- Nutritional therapy can reduce the burden of depression management in low income countries: A review.IBRO neuroscience reports · 2021Review
- Gut Hormones as Potential Therapeutic Targets or Biomarkers of Response in Depression: The Case of Motilin.Life (Basel, Switzerland) · 2021Review
- Article
- The Therapeutic Potential of Psilocybin.Molecules (Basel, Switzerland) · 2021Review
- The Role of Growth Hormone in Depression: A Human Model.Frontiers in neuroscience · 2021Article
- State-of-the-Art: Inflammatory and Metabolic Markers in Mood Disorders.Life (Basel, Switzerland) · 2020Review
- Neuroinflammation and glial cell activation in mental disorders.Brain, behavior, & immunity - health · 2020Review
- Vasopressin Surrogate Marker Copeptin as a Potential Novel Endocrine Biomarker for Antidepressant Treatment Response in Major Depression: A Pilot Study.Frontiers in psychiatry · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is currently recognized as a crucial problem in everyday clinical practice, in light of ever-increasing rates of prevalence, as well as disability, morbidity, and mortality related to this disorder. Currently available antidepressant drugs are notoriously problematic, with suboptimal remission rates and troubling side-effect profiles. Their mechanisms of action focus on the monoamine hypothesis for depression, which centers on the disruption of serotonergic, noradrenergic, and dopaminergic neurotransmission in the brain. Nevertheless, views on the pathophysiology of depression have evolved notably, and the comprehension of depression as a complex neuroendocrine disorder with important systemic implications has sparked interest in a myriad of novel neuropsychopharmacological approaches. Innovative pharmacological targets beyond monoamines include glutamatergic and GABAergic neurotransmission, brain-derived neurotrophic factor, various endocrine axes, as well as several neurosteroids, neuropeptides, opioids, endocannabinoids and endovanilloids. This review summarizes current knowledge on these pharmacological targets and their potential utility in the clinical management of depression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.